Phase 1 N=13 Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Healthy Participants
Primary: Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin — 3.80; 6.47 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=106 Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Neovascular (Wet) Age-Related Macular Degeneration
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 20; 20; 13; 13 Participants
Phase 3 N=10,160 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases
Phase 2 N=11 The University of Michigan Wellness for Liver Health Study
Nonalcoholic Fatty Liver Disease
Primary: Change in Liver Fat Content Using Liver MRI-derived Proton Density Fat Fraction — -7.06 percentage of liver lobe fat
Phase 1 N=14 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 894416 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 371.77; 526.50 Nanomole*hour…
N/A N=117 Effectiveness and Implementation of the HiBalance Program in Clinical Practice
Parkinson Disease
Primary: Change in Mini-BESTest Score From Baseline at 1 Week Post Intervention. — 2.0; -0.2 score on a scale — p=< 0.001
N/A N=25 Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery
Hypoglycemia, Reactive · Hypoglycemia
Primary: Percentage of Time Sensor Glucose <70 mg/dL in the Masked Versus the Unmasked Phase. — 4.7; 2.9 Percentage of time — p=0.04
Phase 2 N=109 A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Uterine Serous Carcinoma
Primary: Objective Response Rate (ORR) — 26 Percentage of participants
Phase 2 N=135 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
Asthma
Primary: Time to First Composite Asthma Exacerbations (CompEX) Event — NA; 45.4 weeks — p=0.6835
Phase 2 N=47 Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
Graft-versus-host-disease (GVHD)
Primary: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint — 49 percentage of participants
Phase 3 N=267 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
Clostridium Difficile Infection (CDI)
Primary: Efficacy of RBX2660 Compared to Placebo Through 8 Weeks — 57.5; 70.6 Model-estimated percent of participants
N/A N=592 Retrospective Independent Safety Review of Closed Irrisept Study
Adverse Events
Primary: All Adverse Events — 894; 962 Adverse Events
N/A N=25 Measurement of Cerebral Blood Flow Using Transcranial Doppler Ultrasound in Children With Sickle Cell Disease
Sickle Cell Disease
Primary: Measurement of Time Average Mean of the Maximum (TAMM) in cm/Sec in Cerebral Arteries Using 2 Different Ultrasound Machines. — 120; 120 cm/sec
Phase 2 N=126 SPI-1005 for the Treatment of Patients With Meniere's Disease
Meniere's Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 19; 20; 20; 15 Participants
Phase 3 N=201 The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Critical Limb Ischemia
Primary: Number of Participants With Primary Patency — 70; 38 Participants